SAN DIEGO — Reduced-intensity dosing of talquetamab may improve tolerability without compromising efficacy among patients with relapsed or refractory multiple myeloma, according to study results.
Most patients in the phase 1/phase 2 MonumenTAL-1 study who responded to the agent and then switched to lower or less frequent doses maintained or deepened responses, findings presented at ASH Annual Meeting showed.
In addition, treatment-emergent adverse events generally improved among those who switched.
“These data support flexibility to adjust dosing of talquetamab [for] responders to
